EMERYVILLE, Calif. – April 5, 2012 – NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY) a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide® compounds for the topical treatment and prevention of infections, today announced it has launched its CEO Blog designed to provide Company perspectives on industry news and topics of interest in a timely fashion...
Read more »